- Home
- NRXP vs KALA Comparison
NRXP vs KALA Comparison
Compare NRXP & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- KALA
- Stock Information
- Founded
- NRXP 2015
- KALA 2009
- Country
- NRXP United States
- KALA United States
- Employees
- NRXP N/A
- KALA N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- KALA Health Care
- Exchange
- NRXP Nasdaq
- KALA Nasdaq
- Market Cap
- NRXP 32.6M
- KALA 26.2M
- IPO Year
- NRXP N/A
- KALA 2017
- Fundamental
- Price
- NRXP $3.27
- KALA $5.26
- Analyst Decision
- NRXP Strong Buy
- KALA Strong Buy
- Analyst Count
- NRXP 4
- KALA 3
- Target Price
- NRXP $28.50
- KALA $14.00
- AVG Volume (30 Days)
- NRXP 298.7K
- KALA 64.7K
- Earning Date
- NRXP 08-13-2025
- KALA 08-05-2025
- Dividend Yield
- NRXP N/A
- KALA N/A
- EPS Growth
- NRXP N/A
- KALA N/A
- EPS
- NRXP N/A
- KALA N/A
- Revenue
- NRXP N/A
- KALA N/A
- Revenue This Year
- NRXP N/A
- KALA N/A
- Revenue Next Year
- NRXP N/A
- KALA N/A
- P/E Ratio
- NRXP N/A
- KALA N/A
- Revenue Growth
- NRXP N/A
- KALA N/A
- 52 Week Low
- NRXP $1.10
- KALA $2.92
- 52 Week High
- NRXP $6.01
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- NRXP 66.15
- KALA 68.75
- Support Level
- NRXP $2.90
- KALA $3.82
- Resistance Level
- NRXP $3.61
- KALA $4.41
- Average True Range (ATR)
- NRXP 0.28
- KALA 0.42
- MACD
- NRXP -0.03
- KALA 0.07
- Stochastic Oscillator
- NRXP 64.59
- KALA 92.00
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.